Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels

por Hol, L, Wilschut, J A, van Ballegooijen, M, van Vuuren, A J, van der Valk, H, Reijerink, J C I Y, van der Togt, A C M, Kuipers, E J, Habbema, J D F, van Leerdam, M E
Publicado 2009

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

por Ellis, Paul, Barrett-Lee, Peter, Johnson, Lindsay, Cameron, David, Wardley, Andrew, O'Reilly, Susan, Verrill, Mark, Smith, Ian, Yarnold, John, Coleman, Robert, Earl, Helena, Canney, Peter, Twelves, Chris, Poole, Christopher, Bloomfield, David, Hopwood, Penelope, Johnston, Stephen, Dowsett, Mitchell, Bartlett, John MS, Ellis, Ian, Peckitt, Clare, Hall, Emma, Bliss, Judith M
Publicado 2009

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma

por Starling, N, Okines, A, Cunningham, D, Allum, W, Wotherspoon, A, Benson, M, Thompson, J, Thomas, J, Brown, G, Riddell, A, Stavridi, F, Ashley, S, Oates, J, Chau, I
Publicado 2009

Hypoxia-inducible factor-1α and -2α are expressed in most rectal cancers but only hypoxia-inducible factor-1α is associated with prognosis

por Rasheed, S, Harris, A L, Tekkis, P P, Turley, H, Silver, A, McDonald, P J, Talbot, I C, Glynne-Jones, R, Northover, J M A, Guenther, T
Publicado 2009

Expression of COX-2, NF-κB-p65, NF-κB-p50 and IKKα in malignant and adjacent normal human colorectal tissue

por Charalambous, M P, Lightfoot, T, Speirs, V, Horgan, K, Gooderham, N J
Publicado 2009

High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series

por Ahmed, H U, Zacharakis, E, Dudderidge, T, Armitage, J N, Scott, R, Calleary, J, Illing, R, Kirkham, A, Freeman, A, Ogden, C, Allen, C, Emberton, M
Publicado 2009

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer

por Cocco, E, Bellone, S, El-Sahwi, K, Cargnelutti, M, Casagrande, F, Buza, N, Tavassoli, F A, Siegel, E R, Visintin, I, Ratner, E, Silasi, D-A, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Publicado 2009

Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study

por Wethal, T, Lund, M-B, Edvardsen, T, Fosså, S D, Pripp, A H, Holte, H, Kjekshus, J, Fosså, A
Publicado 2009

Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours

por Jacob, K, Albrecht, S, Sollier, C, Faury, D, Sader, E, Montpetit, A, Serre, D, Hauser, P, Garami, M, Bognar, L, Hanzely, Z, Montes, J L, Atkinson, J, Farmer, J-P, Bouffet, E, Hawkins, C, Tabori, U, Jabado, N
Publicado 2009

MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer

por Ng, E K O, Tsang, W P, Ng, S S M, Jin, H C, Yu, J, Li, J J, Röcken, C, Ebert, M P A, Kwok, T T, Sung, J J Y
Publicado 2009

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

por Loupakis, F, Ruzzo, A, Cremolini, C, Vincenzi, B, Salvatore, L, Santini, D, Masi, G, Stasi, I, Canestrari, E, Rulli, E, Floriani, I, Bencardino, K, Galluccio, N, Catalano, V, Tonini, G, Magnani, M, Fontanini, G, Basolo, F, Falcone, A, Graziano, F
Publicado 2009

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53

por Canner, J A, Sobo, M, Ball, S, Hutzen, B, DeAngelis, S, Willis, W, Studebaker, A W, Ding, K, Wang, S, Yang, D, Lin, J
Publicado 2009

Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines

por Bergman, A M, Pinedo, H M, Talianidis, I, Veerman, G, Loves, W J P, van der Wilt, C L, Peters, G J
Publicado 2003

Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas

por Martinho, O, Longatto-Filho, A, Lambros, M B K, Martins, A, Pinheiro, C, Silva, A, Pardal, F, Amorim, J, Mackay, A, Milanezi, F, Tamber, N, Fenwick, K, Ashworth, A, Reis-Filho, J S, Lopes, J M, Reis, R M
Publicado 2009

Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB(2)

por Olea-Herrero, N, Vara, D, Malagarie-Cazenave, S, Díaz-Laviada, I
Publicado 2009

Social and geographical factors affecting access to treatment of lung cancer

por Crawford, S M, Sauerzapf, V, Haynes, R, Zhao, H, Forman, D, Jones, A P
Publicado 2009

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

por Negoro, S, Masuda, N, Takada, Y, Sugiura, T, Kudoh, S, Katakami, N, Ariyoshi, Y, Ohashi, Y, Niitani, H, Fukuoka, M
Publicado 2003

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

por Ulrich-Pur, H, Raderer, M, Verena Kornek, G, Schüll, B, Schmid, K, Haider, K, Kwasny, W, Depisch, D, Schneeweiss, B, Lang, F, Scheithauer, W
Publicado 2003

Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer

por Bauernhofer, T, Kuss, I, Friebe-Hoffmann, U, Baum, A S, Dworacki, G, Vonderhaar, B K, Whiteside, T L
Publicado 2003

Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer

por Matsumoto, H, Matsuyama, H, Fukunaga, K, Yoshihiro, S, Wada, T, Naito, K
Publicado 2004